LEADER 01982nam  2200529 a 450 
001 9910452883303321
005 20200520144314.0
010   $a1-61470-438-4
035   $a(CKB)2550000001042789
035   $a(EBL)3020570
035   $a(SSID)ssj0000883450
035   $a(PQKBManifestationID)12383667
035   $a(PQKBTitleCode)TC0000883450
035   $a(PQKBWorkID)10924195
035   $a(PQKB)10739245
035   $a(MiAaPQ)EBC3020570
035   $a(Au-PeEL)EBL3020570
035   $a(CaPaEBR)ebr10677961
035   $a(OCoLC)839305329
035   $a(EXLCZ)992550000001042789
100   $a20091001d2010      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aNonprescription drugs$b[electronic resource] $econsidering a new class for behind-the-counter drugs /$fLars P. Eliassen, editor
210   $aNew York $cNova Science Publishers$dc2010
215   $a1 online resource (209 p.)
225 1 $aPharmacology-research, safety testing and regulation series
300   $aDescription based upon print version of record.
311   $a1-60741-961-0 
320   $aIncludes bibliographical references and index.
327   $aNonprescription drugs : considerations regarding a behind-the-counter drug class / Government Accountability Office -- Food and Drug Administration behind the counter availability of certain drugs, public meeting / United States Department of Health and Human Services.
410  0$aPharmacology-research, safety testing, and regulation series.
606   $aDrugs, Nonprescription$xGovernment policy$zUnited States
608   $aElectronic books.
615  0$aDrugs, Nonprescription$xGovernment policy
676   $a615/.1
701   $aEliassen$b Lars P$0991816
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910452883303321
996   $aNonprescription drugs$92269808
997   $aUNINA